NLS Pharmaceutics GAAP EPS of -$2.16
Seeking Alpha News (Fri, 1-May 8:48 AM ET)
NewcelX Posts 2025 Results and Bolsters Funding to Accelerate Type 1 Diabetes Program
TipRanks (Thu, 30-Apr 10:03 AM ET)
Globe Newswire (Thu, 30-Apr 8:15 AM ET)
Top NewcelX Insiders Quietly Make Bold Moves With Fresh Share Purchases
TipRanks (Wed, 29-Apr 10:02 PM ET)
Globe Newswire (Mon, 20-Apr 7:37 AM ET)
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Globe Newswire (Wed, 1-Apr 7:21 AM ET)
PRNewswire (Mon, 9-Mar 7:00 AM ET)
PRNewswire (Thu, 12-Feb 7:00 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
Newcelx Ltd. - trades on the NASDAQ stock market under the symbol NCEL.
As of May 1, 2026, NCEL stock price declined to $3.85 with 33,590 million shares trading.
NCEL has a beta of 3.95, meaning it tends to be more sensitive to market movements. NCEL has a correlation of 0.14 to the broad based SPY ETF.
NCEL has a market cap of $20.58 million. This is considered a Sub-Micro Cap stock.
NCEL support price is $3.96 and resistance is $4.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NCEL shares will trade within this expected range on the day.